Does High Total Ischemic Time Have a Different Impact in Patients with st-elevation Myocardial Infarction Depending on Renal Function ?

Harutyun Petrosyan, MD¹, Hamlet Hayrapetyan, MD, PHD¹, Anastasiia Veprintseva, MD¹, Shahen Torozyan, MD², Norik Ghazaryan, MD, PHD^3,4

¹Urgent cardiology department, Erebouni Medical Center, Yerevan, Armenia

²Interventional cardiology department, Erebouni Medical Center, Yerevan, Armenia

³Surgery, Astghik Medical Center, Yerevan, Armenia

⁴Surgery, Ust-Ischim District Hospital, Omsk, Russia

^*Corresponding author: Norik Ghazaryan, MD, PHD, Vanatur 497 Hrazdan, Armenia.

Received: 09 February 2024; Accepted: 20 February 2024; Published: 04 March 2024

Abbreviations:

GFR: Glomerular Filtration Rate; RF: Renal Function; ACS: Acute Coronary Syndrome; PCI: percutaneous coronary intervention; RD: Renal Dysfunction; STEMI: ST-segment Elevation Myocardial Infarction; TIT: Total Ischemic Time; LE: Lung Edema; CS: Cardiogenic Shock

Introduction

A lot of adults suffer from chronic kidney disease, which they learn about when they get to the hospital for other reasons.[1] There is also an increased risk of cardiovascular diseases associated with decreased renal function (RF).[2-4] In patients with acute myocardial infarction, impaired renal function at the time of admission should indicate an increased risk of nosocomial complications.[5] Several studies have shown that even minor changes in glomerular filtration rate (GFR) increase the risk of developing de novo coronary heart disease or death after the first myocardial infarction.[6-8]

Patients with impaired RF had a worse outcome than patients with normal RF after acute coronary syndrome (ACS), which includes acute myocardial infarction, percutaneous coronary intervention (PCI) and coronary artery bypass grafting.[9] With the exception of caution regarding prescribed dosages and more liberal use of revascularization, current recommendations offer patients with renal insufficiency the same therapy as other patients with ACS.[10,11] Since clinicians may not be aware of impaired renal function, a special offer has been developed to help identify patients with cardiovascular diseases and impaired renal function.[12] Given this high risk, patients with renal dysfunction (RD) may benefit more directly from the intrusive technique than those without RD; however, the risk of adverse outcomes is also higher in patients with renal dysfunction.[13,14] Several laboratory tests were conducted to determine RF. GFR is the most reliable indicator of RF evaluation.[15] It is extremely important to understand what leads to poor outcomes in patients with renal insufficiency. Clinical manifestations of ACS in patients with RF differ markedly from those in patients without RF in the general population.[16-21] Firstly, the prevalence of chest discomfort in patients with ACS is inversely proportional to the stage of RD. As GFR decreases, the frequency of chest discomfort gradually decreases.[21] There is no doubt that myocardial reperfusion with primary PCI is the main therapy for acute ST-segment elevation myocardial infarction (STEMI), and it should be performed as soon as possible. In patients with RD, ischemia may last longer due to distortion of clinical symptoms. The total time of ischemia (TIT), measured from the onset of symptoms to reperfusion therapy, is crucial for the prognosis of patients with STEMI, and it should be carefully considered when determining the time to reperfusion.[22]  It should also be noted that, TIT independently correlated with in-hospital mortality after PCI in patients with STEMI with an ejection fraction below 50%.[23] Also, according to the results of Gao and colleagues’s study, acute kidney injury is a significant risk factors for hospital death in patients with STEMI.[23] As mentioned earlier, TIT is a prognostic risk factor in patients with STEMI, and the purpose of this study was to compare the effect of high TIT on hospital-acquired complications and prognosis in patients with STEMI with different kidney functions.

Patients and Methods

Study design and population

This is a prospective, observational, single-center study, which was carried out at Erebuni Medical Center in Yerevan, Armenia in 2017-2022 years. A total of 224 STEMI patients with ≥ 6 hours TIT were selected for this study and all them categorised into three groups according to GFR. Total ischemic time was defined as the time from the onset of chest pain to the first balloon inflation during primary PCI.[10] Group 1 consisted of 73 patients whose GFR was < 60 ml/min/1.73 m2. Group 2 consisted of 72 patients with GFR ≥ 60 ml/min/1.73 m2 and < 90 ml/min/1.73 m2 and Group 3 consisted of 79 patients with GFR ≥ 90 ml/min/1.73 m2. GFR was estimated with the modification of diet in renal disease formula, which is calculated by using creatinine, age, gender, and race.[24] The patients were all white. All patients' demographic, angiographic, and clinical data, including age, gender, and cardiovascular risk factors like hypertension, diabetes, and STEMI localization, were gathered during the first few hours after admission. Iohexol was used as a contrast agent. Before and after PCI, RF was assessed for all patients. The European Society of Cardiology guidelines defined all variables and the criteria for the diagnosis of STEMI and acute heart failure,[11] and were guided by that.

All subjects participated voluntarily. Informed consent was obtained from all individual participants included in the study. Ethics committee of "Erebuni" Medical Center issued approval 01/483. All procedures performed in studies involving human participants or on human tissue were by the ethical standards of the institutional and/or national research committee and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards.

Treatment protocol

Patients with severe valvular heart disease, cancer, acute cerebrovascular disease, or other serious non-cardiac medical conditions with a life expectancy of less than one year were excluded from the study. Patients who declined to give written consent were also excluded. Following the ESC Guidelines on acute myocardial infarction in patients with ST-segment elevation, all enrolled STEMI patients in three groups underwent primary PCI using a standard technique through the radial artery route.[11] Every patient received as many stents as were deemed clinically necessary for the infarct-related artery. Aspirin, clopidogrel, statins, beta-blockers, heparin, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, diuretics, and other medications were given to all patients in the groups as part of standard pharmacological treatment for STEMI following current guidelines (Table I).

Table I: The groups were comparable in terms of received drugs

ACE, angiotensin-converting enzyme; ARBs, angiotensin II receptor blockers, LMWHs, low molecular weight heparins. P < 0.05 is considered significant.

Study outcomes

The primary outcome was a 6-month death rate after admission for STEMI, and secondary outcomes were in-hospital death and complication of STEMI with lung edema (LE) or cardiogenic shock(CS). At the end of 6 months after admission, the rates of complications were compared between groups.

Statistical analysis

Software called SPSS 26.0 (SPSS Inc., USA) was used to digitize and collect survey data. Standard statistical techniques were applied. Each calculated p-value had a two-tailed significance level of 0.05 to be considered statistically significant. While categorical variables are summarized based on the frequency and group percentage, continuous variables were summarized as mean and standard deviation.

The analysis of patients’ data included in the study was performed using the following statistical tests:

– The ANOVA test was used to compare continuous variables between the three groups in the study.

– Student’s t-test was used to compare continuous variables between two subgroups of patients.

– Pearson’s chi-squared test was used to compare the frequencies of the indicators were compared in the study.

– Categorical variables between groups were analyzed using Fisher’s z-transformation test as necessary.

Results

A total of 224 patients with STEMI were included. The mean GFR in Group 1 was 48.4±10.4 ml/min/1.73 m2, in Group 2 73.7±8.4 ml/ min/1.73 m2, and in Group 3 105.9±16.0 ml/ min/1.73 m2 (p < 0.001). The mean TIT in Group 1 was 8.5±1.9 hours, while in Group 2 it was 8.4±1.8 hours and in Group 3 it was 8.9±1.9 hours (p=0.29). The average age of patients in Group 1 was 67.5±9.6 years old, 67.8±7.9 years old in Group 2, and 65.1±8.0 years old in Group 3 (p = 0.079). The percentage of males was 63.0% in Group 1, 63.9% in Group 2, and 72.2% in Group 3 (p = 0.42). There was a high prevalence of cardiac risk factors and/or comorbid conditions in the groups: 23.3% in Group 1, 25.0% in Group 2, and 22.8% in Group 3 had a history of diabetes (p = 0.95), while 72.6% in Group 1, 70.8% in Group 2, and 64.6% in Group 3 had a history of hypertension (p = 0.53). Prior MI was reported by 11.0 % in Group 1, 9.7% in Group 2, and 2.5% in Group 3 (p = 0.1). Anterior STEMI was present in 52.1% of Group 1, 41.7% of Group 2, and 40.5% of Group 3 (p = 0.3). (Table II). The incidence of LE and CS was significantly lower in Group 3 (1.3%) compared to Group 1 (15.1%) and Group 2 (6.9%) (p = 0.006). LE and CS rates did not differ significantly between Group 2 and Group 3 (p =0.103). No significant between-group differences were found for in-hospital death in Group 1 (4.1%), Group 2 (1.4%), and Group 3 (0) (p = 0.15). In the first group, 4 patients needed dialysis, in the second group 2 patient and in the third group also 2 patients. There was no statistical difference between the groups (P = 0.56). Also, the authors found significant between-group differences for 6-month death. Group 1 (12.3%) showed a considerably higher 6-month death rate than Group 2 (2.8 %) and Group 3 (2.5%) (p=0.015. No significant between-group differences were found for the 6-month death rate in Group 2 and Group 3 (p = 0.999). (Table III).

Table II: Baseline demography and clinical characteristics stratified according glomerular filtration rate

EF, ejection fraction GFR; glomerular filtration rate; MI, myocardial infarction; STEMI, ST-elevation myocardial infarction; SD, standard deviation; TIT, total ischemic time.

P < 0.05 is considered significant.

Table III: Effect of high total ischemic time on in-hospital complications and prognosis

P < 0.05 is considered significant.

Discussion

The relationship between TIT and the prognosis following PCI in patients with STEMI has been shown in numerous studies.[23,25] The main finding of this study was the discovery of a clear relationship between RD and in-hospital complications and prognosis in the case of high TIT. The TIT values between groups in the current study did not differ significantly but were higher than optimal in the three groups: the mean TIT in Group 1 was 8.5±1.9, while in Group 2 it was 8.4±1.8 and in Group 3 it was 8.9±1.9 (p=0.29). Our groups differed slightly regarding prior myocardial infarction and ejection fraction. The incidence of prior MI was low in Group 3 (2) compared to Group 1 (8) and Group 2 (7) (P = 0.1). EF was lower in Group 1 (37.8 + 8.7 %) compared to Group 2 (41.1 + 8.7 %) and Group 3 (42.1 + 6.7 %) (P = 0.004) (Table II). The authors reasoned that high TIT must have a more significant impact on patients with RD. Patients with low TIT did not participate in this study. There is no doubt about statistically significant variations in intra-hospital complications and prognosis across patients with various RF if all other data were comparable. In-hospital complications and prognosis varied between STEMI patients who had high TIT and various RF, according to the results of the current study. This means that a rise in the TIT, in the presence of RD, affects more obviously the course of the disease and results in in-hospital complications and prognosis. Our study found that patients with RD and high TIT were more likely to develop complications such as PE or CS. Also, our study proved that revascularization delay has a higher impact on prognosis in STEMI patients with RD. Noteworthy is the fact that there is insufficient data in the literature that would indicate the importance of TIT, especially in patients with RD. This study suggests that TIT value deserves more attention in STEMI patients with RD to make the prognosis more predictable.

Study limitations

There are some limitations to this study. The study's main limitations are its single-center design and small sample size. The second limitation is that RD was diagnosed solely based on GFR calculations at the time of admission, with no prior documentation.

Conclusion

TIT with assessment of renal function are independent predictors of nosocomial complications. This fact is especially important in patients with concomitant pathologies, such as RD. Our study showed that in STEMI patients with RD, a high level of TIT had a great impact on nosocomial complications and prognosis compared to STEMI patients with normal kidney function. In STEMI patients with high TIT, assessing RF may help predict in-hospital complication.

Declerations:

Conflict of Interest Disclosure:

None

Author Contributions:

1. Harutyun Petrosyan - Have treated patients
2. Hamlet Hayrapetyan - Have controlled and coordinated treatment (Head of the Department.)
3. Anastasiia Veprintseva - Worked with the database
4. Shagen Torozyan - Operated patients
5. Norik Ghazaryan - Worked with the database

Funding/Support:

None

Acknowledgments:

The author would like to thank all patients that contributed to the success of the study.

References

1. Mota E, Popa SG, Mota M, et al. Prevalence of chronic kidney disease and its association with cardio-metabolic risk factors in the adult Romanian population: the PREDATORR study. Int Urol Nephrol 47 (2015): 1831-1838.
2. Arnlöv J. Diminished renal function and the incidence of heart failure. Curr Cardiol Rev 5 (2009): 223-227.
3. Jankowski J, Floege J, Fliser D, et al. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation 143 (2021): 1157-1172.
4. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis. 2000; 35 (2000): S117-131.
5. Michalis LK, Stroumbis CS, Pappas K, et al. Treatment of refractory unstable angina in geographically isolated areas without cardiac surgery: invasive versus conservative strategy (TRUCS study). Eur Heart J 21 (2000): 1954-1959.
6. Chaitman BR, McMahon RP, Terrin M, et al. Impact of treatment strategy on predischarge exercise test in the Thrombolysis in Myocardial Infarction (TIMI) II Trial. Am J Cardiol 71 (1993): 131-138.
7. Kim JW, Lim DS, Sun K, et al. Stenting or MIDCAB using ministernotomy for revascularization of proximal left anterior descending artery? Int J Cardiol 99 (2005): 437-441.
8. Germing A, Lindstaedt M, Ulrich S, et al. Normal angiogram in acute coronary syndrome-preangiographic risk stratification, angiographic findings and follow-up. Int J Cardiol 99 (2005): 19-23.
9. Al Suwaidi J, Reddan DN, Williams K, et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 106 (2002): 974-980.
10. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 42 (2021): 1289-1367.
11. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39 (2018): 119-177.
12. Brosius FC 3rd, Hostetter TH, Kelepouris E, et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney and Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: Developed in Collaboration With the National Kidney Foundation. Hypertension 48 (2006): 751-755.
13. Chiamvimonvat V, Goodman SG, Langer A, et al. Prognostic value of dipyridamole SPECT imaging in low-risk patients after myocardial infarction. J Nucl Cardiol 8 (2001): 136-143.
14. Schächinger V, Kasper W, Zeiher AM. Adjunctive intracoronary urokinase therapy during percutaneous transluminal coronary angioplasty. Am J Cardiol 77 (1996): 1174-1178.
15. Fuhrmann M, Santamaria AS, Scott R, et al. Analytical Validation of GFRNMR: A Blood-Based Multiple Biomarker Assay for Accurate Estimation of Glomerular Filtration Rate. Diagnostics (Basel) 12 (2022): 1120.
16. Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation 121 (2010): 357-365.
17. Herzog CA, Littrell K, Arko C, et al. Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: a collaborative project of the United States Renal Data System and the National Registry of Myocardial Infarction. Circulation 116 (2007): 1465-1472.
18. Sosnov J, Lessard D, Goldberg RJ, et al. Differential symptoms of acute myocardial infarction in patients with kidney disease: a community-wide perspective. Am J Kidney Dis 47 (2006): 378-384.
19. Szummer K, Lundman P, Jacobson SH, et al. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation 120 (2009): 851-858.
20. Shroff GR, Frederick PD, Herzog CA. Renal failure and acute myocardial infarction: clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease. A collaborative project of the United States Renal Data System/National Institutes of Health and the National Registry of Myocardial Infarction. Am Heart J 163 (2012): 399-406.
21. Szummer K, Lundman P, Jacobson SH, et al. Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register. J Intern Med 268 (2010): 40-49.
22. Song JX, Zhu L, Lee CY, et al. Total ischemic time and outcomes for patients with ST-elevation myocardial infarction: does time of admission make a difference? J Geriatr Cardiol 13 (2016): 658-664.
23. Gao N, Qi X, Dang Y, et al. Association between total ischemic time and in-hospital mortality after emergency PCI in patients with acute ST-segment elevation myocardial infarction: a retrospective study. BMC Cardiovasc Disord 22 (2022): 80.
24. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999): 461-470.
25. Petrosyan H, Hayrapetyan H, Torozyan S, et al. Total Ischemic Time on In-Hospital Complication Predictor in ST-Elevation Myocardial Infarction (STEMI) Patients With Renal Dysfunction. Cureus 15 (2023): e33903.